Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0KTRKE
ADC Name	PF-06664178
Synonyms	PF06664178; PF6664178; PF 6664178 Click to Show/Hide
Organization	Pfizer Inc.
Drug Status	Terminated in phase 1
Indication	In total 1 Indication(s) Lung cancer [ICD11:2C25] Terminated in phase 1
Drug-to-Antibody Ratio	2
Structure
	3D MOL	2D MOL
Antibody Name	PF-06478924		Antibody Info
Antigen Name	Tumor-associated calcium signal transducer 2 (TACSTD2)		Antigen Info
Payload Name	Auristatin 0101		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	AcLys-Val-Cit-PABC		Linker Info
Conjugate Type	Site-specific conjugation through the transglutaminase tag (LLQGA) located at the C-terminus of the antibody heavy chain by an transglutaminase (mTgase).
Combination Type	AcLys-VC-PABC-PF-06380101
TTD ID	D0G4RI

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT02122146	Phase 1	A phase 1, dose escalation study of Pf-06664178 in patients with locally advanced or metastatic solid tumors.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	0.00%
Patients Enrolled	Advanced solid tumors resistant to standard therapy, or for which no other therapy was available, and at least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
Administration Dosage	Once every 21 days as an intravenous infusion over approximately 60 min, doses starting from 0.15 mg/kg to 6.14 mg/kg.
*Related Clinical Trial*
NCT Number	NCT02122146	Clinical Status	Phase 1
Clinical Description	A phase 1, dose escalation study of Pf-06664178 in patients with locally advanced or metastatic solid tumors.
Primary Endpoint	In the 29 response-evaluable patients,the best overall response observed was limited to stable disease (SD) in 11 patients(37.90%) with PR or CR.
Other Endpoint	Doses explored ranged from 0.15 mg/kg to 4.80 mg/kg. Doses of 3.60 mg/kg,4.20 mg/kg and 4.80 mg/kg were considered intolerable due to DLTs. MTD and RP2D were not determined.

References

Ref 1	A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018 Oct;36(5):836-847.